These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 339937)

  • 21. Comparison of oxprenolol plus chlorthalidone in fixed combination against chlorthalidone alone in mild to moderate essential hypertension; a clinical trial.
    Gruppillo P; Tomasi AM; Masoni A; Finzi C
    G Ital Cardiol; 1980; 10(4):476-9. PubMed ID: 7002694
    [No Abstract]   [Full Text] [Related]  

  • 22. Once daily administration of a beta-blocker in hypertension.
    Watt M; Duncan TD
    N Z Med J; 1978 Feb; 87(606):126-8. PubMed ID: 274648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension.
    Masoni A; Tomasi AM; Pirani R; Lazzaretto R; Ambroso G
    G Ital Cardiol; 1981; 11(12):2105-9. PubMed ID: 7346306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Reduction of left ventricular hypertrophy and increased tolerance to exertion in hypertensive patients after antihypertensive therapy with slow-release oxprenolol and chlorthalidone].
    Sau F; Seguro C; Alberti D; Cherchi A
    Cardiologia; 1986 Sep; 31(9):701-8. PubMed ID: 2949838
    [No Abstract]   [Full Text] [Related]  

  • 25. Slow release oxprenolol in angina pectoris [proceedings].
    Goldstraw PW; Taylor SH; Thadani U; Watt SJ
    Br J Clin Pharmacol; 1977 Jun; 4(3):387P. PubMed ID: 332219
    [No Abstract]   [Full Text] [Related]  

  • 26. The treatment of hypertension in older patients: a comparative study between a diuretic, a beta-receptor antagonist and their fixed combination.
    Forrest WA
    Practitioner; 1982 Apr; 226(1366):777-8. PubMed ID: 7045851
    [No Abstract]   [Full Text] [Related]  

  • 27. [An example of an acceptable combination in the treatment of arterial hypertension].
    Menard J; Plouin PF; Gouin F; Corvol P; Milliez P
    Sem Hop; 1978 Feb; 54(4):201-6. PubMed ID: 208167
    [No Abstract]   [Full Text] [Related]  

  • 28. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
    Resnekov EB; Havard CW
    Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    Clin Sci Mol Med Suppl; 1976 Dec; 3():559s-561s. PubMed ID: 1071681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of oxprenolol, triamterene, and dihydralazine in the treatment of essential hypertension].
    Gerc V; Numić N
    Med Arh; 1980; 34(1):51-9. PubMed ID: 7007752
    [No Abstract]   [Full Text] [Related]  

  • 32. [Advantages of a fixed association of oxprenolol-chlorthalidone, as opposed to chlorthalidone alone, in the treatment of chronic essential arterial hypertension].
    Baronchelli A; Agosta R; Verdecchia P; Bichisao E
    Clin Ter; 1981 Apr; 97(1):63-9. PubMed ID: 7026137
    [No Abstract]   [Full Text] [Related]  

  • 33. A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
    Muiesan G; Agabiti-Rosei E; Buoninconti R; Carotti A; Fariello R; Innocenti P; Toso M; Valori C; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):249-55. PubMed ID: 7309298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Slow-Trasicor in the treatment of angina pectoris].
    Giec L; Trusz-Gluza M; Hübner D; Olwiński M
    Wiad Lek; 1984 Sep; 37(18):1401-6. PubMed ID: 6397916
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of oxprenolol vs methyldopa as second-line antihypertensive agents in the elderly.
    Traub YM
    Arch Intern Med; 1988 Jan; 148(1):77-80. PubMed ID: 3276279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of chronic administration of the fixed combination slow-release oxprenolol-chlorthalidone on left ventricular hypertrophy in hypertensive patients. Echocardiographic study.
    Bertoni T; Alberti D; Peloso A; Francucci BM; De Ambroggi L
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):148-52. PubMed ID: 2970442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxprenolol in hypertension.
    Marshall AJ; Barritt DW
    Br J Clin Pract; 1973 Sep; 27(9):337-40. PubMed ID: 4595073
    [No Abstract]   [Full Text] [Related]  

  • 38. Oxprenolol slow-release with cyclopenthiazide KCl in the treatment of essential hypertension. A multicentre general practice study.
    Levenstein JH
    S Afr Med J; 1981 Jun; 59(25):893-9. PubMed ID: 7015537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 40. Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice.
    Ebbut AF; Elsdon-Dew RW; Murphy JE
    J Int Med Res; 1978; 6(6):494-8. PubMed ID: 720740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.